Overview
Compare with Phio Pharmaceuticals Corp., JUPITER NEUROSCIENCES, INC. or BIOADAPTIVES, INC., or pick any stock.
- TickerSKVI on OTC1
- IndustryPharmaceutical Preparations1
- HeadquartersLas Vegas, Nevada1
- Incorporated inNV2
- Business address6320 S Sandhill Road, Unit 9, Las Vegas, Nv 891202
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
LICENSING : We develop topical prescription and over-the-counter products enhanced with Invisicare to license to pharmaceutical and consumer goods companies around the world for an upfront fee and ongoing royalties.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin46¢$496.1K
- Interest54¢$572.2K
Out of $20.0K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $20.0K | $20.0K |
| Gross profit | $20.0K | $20.0K |
| Depreciation and amortization | $20.2K | $20.4K |
| Selling general and administrative | $496.1K | $589.2K |
| Total operating expenses | $516.3K | $609.6K |
| Loss from operations | -$496.3K | -$589.6K |
| Other income | $4.5K | $697.2K |
| Interest expense | -$572.2K | -$669.4K |
| Gain/(loss) on change in derivative liability | -$3.9K | |
| Total other income (expense) | -$567.7K | $23.9K |
| Net loss | -$1.1M | -$565.7K |
| Basic loss per common share | -$0 | -$0 |
| Basic weighted average common shares outstanding | 5.4M shares | 5.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash | $2.6K | $10.3K |
| Accounts receivable | $5.0K | $5.0K |
| Due from related party | $17.6K | $17.6K |
| Prepaid expense and other current assets | $2.3K | $9.1K |
| Total current assets | $27.5K | $42.0K |
| Patents and trademarks, net | $100.0K | $116.2K |
| Total assets | $127.6K | $158.2K |
| Accounts payable and accrued liabilities | $1.3M | $859.0K |
| Accrued interest payable | $3.4M | $2.8M |
| Due to related party | $45.0K | $13.4K |
| Loans payable | $10.0K | |
| Convertible notes payable | $352.1K | |
| Total current liabilities | $5.0M | $3.7M |
| Convertible notes payable related party | $5.4M | $5.4M |
| Convertible notes payable | $352.1K | |
| Total liabilities | $10.4M | $9.4M |
| Common stock; $0.001 par value; 200,000,000 shares authorized; 5,403,843 and 5,316,843 shares issued and outstanding at December 31, 2025 and 2024, respectively | $5.4K | $5.3K |
| Shares payable | $10.0K | |
| Additional paid-in capital | $30.7M | $30.7M |
| Accumulated deficit | -$41.0M | -$39.9M |
| Total stockholders' deficit | -$10.3M | -$9.2M |
| Total liabilities and stockholders' deficit | $127.6K | $158.2K |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 |
| Common Stock, Shares Authorized | 200.0M shares | 200.0M shares |
| Common Stock, Shares, Issued | 5.4M shares | 5.3M shares |
| Common Stock, Shares, Outstanding | 5.4M shares | 5.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash | $2.6K | $10.3K |
| Accounts receivable | $5.0K | $5.0K |
| Due from related party | $17.6K | $17.6K |
| Prepaid expense and other current assets | $2.3K | $9.1K |
| Total current assets | $27.5K | $42.0K |
| Patents and trademarks, net | $100.0K | $116.2K |
| Total assets | $127.6K | $158.2K |
| Accounts payable and accrued liabilities | $1.3M | $859.0K |
| Accrued interest payable | $3.4M | $2.8M |
| Due to related party | $45.0K | $13.4K |
| Loans payable | $10.0K | |
| Convertible notes payable | $352.1K | |
| Total current liabilities | $5.0M | $3.7M |
| Convertible notes payable related party | $5.4M | $5.4M |
| Convertible notes payable | $352.1K | |
| Total liabilities | $10.4M | $9.4M |
| Common stock; $0.001 par value; 200,000,000 shares authorized; 5,403,843 and 5,316,843 shares issued and outstanding at December 31, 2025 and 2024, respectively | $5.4K | $5.3K |
| Shares payable | $10.0K | |
| Additional paid-in capital | $30.7M | $30.7M |
| Accumulated deficit | -$41.0M | -$39.9M |
| Total stockholders' deficit | -$10.3M | -$9.2M |
| Total liabilities and stockholders' deficit | $127.6K | $158.2K |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 |
| Common Stock, Shares Authorized | 200.0M shares | 200.0M shares |
| Common Stock, Shares, Issued | 5.4M shares | 5.3M shares |
| Common Stock, Shares, Outstanding | 5.4M shares | 5.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$1.1M | -$565.7K |
| Shares issued for services | $68.8K | |
| Depreciation and amortization | $20.2K | $20.4K |
| Amortization of debt discount | $51.0K | |
| (Gain)/loss on settlement of debt | -$697.2K | |
| Gain/(loss) on change in derivative liability | $3.9K | |
| Decrease (Increase) in prepaid assets | $6.8K | -$1.1K |
| Decrease (Increase) in due to related party | $4.0K | |
| Increase (decrease) in accounts payable and accrued liabilities | $394.7K | $420.3K |
| Decrease in due from related party | $31.7K | $7.4K |
| Increase in accrued interest | $572.2K | $618.5K |
| Net cash provided used in operating activities | -$38.4K | -$69.8K |
| Purchase of intangible assets | -$4.1K | -$9.2K |
| Net cash used in investing activities | -$4.1K | -$9.2K |
| Common stock issued for cash | $24.8K | $66.0K |
| Proceeds from notes payable | $10.0K | |
| Proceeds from convertible notes payable | $22.5K | |
| Net cash provided by (used in) financing activities | $34.8K | $88.5K |
| Net change in cash | -$7.7K | $9.4K |
| Derivative liability written off to APIC | $22.4K |
No quarter-by-quarter statement was filed.
What it owns
What SKINVISIBLE, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Finite-lived intangibles, net | $100.0K4 Dec 31, 2025 | $116.2K4 Dec 31, 2024 | −13.9% |
Properties, in its own words
Currently, we do not own any or lease any real estate.
Item 2 of the 10-K filed Mar 31, 2026.3
Leadership
Who has led SKINVISIBLE, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2010201520202025
- Chief executive officerJost Steinbruchel Aug 23, 2007 to Aug 23, 200712
- Chief executive officerTerry Howlett Feb 17, 2006 to Feb 2, 202313
- Chief financial officerJost Steinbruchel Aug 23, 2007 to Aug 23, 200712
- Chief financial officerTerry Howlett Feb 17, 2006 to Feb 2, 202313
Board members and other officers (5)
- Board memberJames David M. St Sep 26, 2017 to Sep 26, 201714
- Board memberBrian Piwek Mar 4, 2008 to Jul 27, 201015
- Board memberJost Steinbruchel Aug 23, 2007 to Aug 29, 200712
- Board memberE. Greg McCartney Sep 5, 2007 to Mar 28, 201716
- Board memberTerry Howlett Feb 17, 2006 to Feb 2, 202313
Former names
- SKINVISIBLE INCSep 14, 1999 to Aug 14, 20192
Timeline
- Jan 23, 20258-K Regulation FD disclosure17
- Oct 3, 20248-K Regulation FD disclosure18
- Jun 4, 20248-K Unregistered sale of shares19
- May 29, 20248-K Regulation FD disclosure20
- Oct 25, 20238-K Change of auditor21
- Jan 13, 20228-K Change of auditor22
- Aug 23, 2007New chief executive Jost Steinbruchel becomes CEO12
- Feb 17, 2006New chief executive Terry Howlett becomes CEO13
Filings
35 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 6 major events, 3 insider forms, 6 other. The latest 20:
- Aug 13, 202610-Q EDGAR
- May 13, 202610-Q EDGAR
- Mar 31, 202610-K EDGAR
- Nov 13, 202510-Q EDGAR
- Aug 13, 202510-Q EDGAR
- May 14, 202510-Q EDGAR
- Apr 14, 202510-K ANNUAL REPORT EDGAR
- Mar 31, 2025NT 10-K EDGAR
- Jan 23, 20258-K EDGAR
- Nov 19, 202410-Q EDGAR
- Nov 14, 2024NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Oct 3, 20248-K EDGAR
- Aug 15, 202410-Q EDGAR
- Aug 14, 2024NT 10-Q EXTENSION EDGAR
- Jun 4, 20248-K EDGAR
- May 29, 20248-K EDGAR
- May 15, 202410-Q QUARTERLY REPORT EDGAR
- Apr 16, 202410-K EDGAR
- Apr 1, 2024NT 10-K EDGAR
- Nov 15, 202310-Q EDGAR
The 35 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How SKINVISIBLE, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSKINVISIBLE, INC.1
- CIK0001085277
- Employer ID (EIN)88-03442193
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company3
- Incorporated inNevada3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address6320 S Sandhill Road, Unit 9, Las Vegas, NV 891201
- Phone702-433-71541
- Shares outstanding5,403,843 as of Aug 13, 202611
- Public float$5.3M as of Jun 30, 20253
- AuditorGreenGrowth CPAs, Los Angeles, California PCAOB ID 65803
- On EDGAR sinceApr 30, 19991
- Filings391 in all: 4 (103), 10-Q (57), 8-K (46), 10QSB (25), NT 10-Q (22), 10-K (19), NT 10-K (17), 5 (13)1
All 33 form types
4/A (9), 10KSB (8), SC 13G (8), DEF 14A (7), PRER14A (7), UPLOAD (7), 3 (5), SC 13D (5), 8-K/A (4), 10-Q/A (3), 5/A (3), PRE 14A (3), S-8 (3), 10-K/A (2), 10KSB/A (2), 10SB12G/A (2), REGDEX (2), SC 13D/A (2), 10QSB/A (1), 10SB12G (1), DEFR14A (1), PREM14A (1), S-1 (1), S-8 POS (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Mar 31, 2026
Quarterly report (10-Q) Aug 13, 2026
Proxy statement (DEF 14A) Oct 19, 2018
Latest 8-K (8-K) Jan 23, 2025
Risk factors and legal proceedings
The risks SKINVISIBLE, INC. names in Item 1A of its 10-K filed Mar 31, 2026: 24 risks under these headings, as written.3
- Risks Related to Our Financial Condition and our Business
- Our investors may lose their entire investment because our financial status creates a doubt whether we will continue as a going concern.
- Our failure to raise additional capital or generate cash flows necessary to expand our operations could reduce our ability to compete successfully and adversely affect our results of operations.
- If we are unable to generate revenues by implementing our business plan, you will lose your entire investment in our company.
- If our products or products that are licensed by our licensees are not deemed desirable and suitable for purchase and we cannot establish a customer base, we may not be able to generate sufficient revenues, which would result in a failure of the business and a loss of any investment one makes in our company.
- If demand for the products that we offer or products that are licensed by our licensees slows, then our business would be materially affected.
- Because we are new in the marketplace, we may not be able to compete effectively and increase market share.
- Because we rely on third parties to manufacture our products, we are subject to factors outside of our control to meet our standards or timelines.
- Like other retailers, distributors and manufacturers of skin care and personal care products, we face an inherent risk of exposure to product liability claims in the event that the use of the products that we sell results in injury.
- If our products become contaminated, our business could be seriously harmed.
- Our business may be adversely affected by unfavorable publicity within the skin care markets.
- As we conduct international business transactions, we will be exposed to local business risks in different countries, which could have a material adverse effect on our financial condition or results of operations.
The other 13 risks
- Because of the nature of our products, we may be subject to government regulations or laws that increase our costs of operations or decrease our ability to generate income.
- Our commercial success depends significantly on our ability to develop and commercialize our potential products without infringing the intellectual property rights of third parties.
- The implementation of our business plan relies on our ability to manage growth. If we are not able to manage the growth, our business plan may not be successfully implemented.
- Our success depends on continuing to hire and retain qualified personnel, including our director and officers and our technical personnel. If we are not successful in attracting and retaining these personnel, our business will suffer.
- If we are unable to attract new distributors and customers, or if our existing distributors and customers do not purchase additional products, the growth of our business and cash flows will be adversely affected.
- Key management personnel may leave us, which could adversely affect our ability to continue operations.
- We have identified a material weakness in our internal controls over financial reporting and we cannot provide assurances that this weakness will be effectively remediated or that additional material weaknesses will not occur in the future.
- Risks Related to Our Securities
- If a market for our common stock does not develop, shareholders may be unable to sell their shares.
- Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.
- We have not paid cash dividends in the past and do not expect to pay cash dividends in the future on our common stock. Any return on investment may be limited to the value of our common stock.
- As a new investor, you will experience substantial dilution as a result of future equity issuances.
- Because we are subject to the “Penny Stock” rules, the level of trading activity in our stock may be reduced.
- Provisions in the Nevada Revised Statutes and our Bylaws could make it very difficult for an investor to bring any legal actions against our directors or officers for violations of their fiduciary duties or could require us to pay any amounts incurred by our directors or officers in any such actions.
Legal proceedings
We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARJames David M. St, Board member
- 15SEC EDGARBrian Piwek, Board member
- 16SEC EDGARE. Greg McCartney, Board member
- 17SEC EDGARRegulation FD disclosure
- 18SEC EDGARRegulation FD disclosure
- 19SEC EDGARUnregistered sale of shares
- 20SEC EDGARRegulation FD disclosure
- 21SEC EDGARChange of auditor
- 22SEC EDGARChange of auditor